Gynofem Healthcare And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 9.92 Cr
- Company Age 2 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.50 M
About Gynofem Healthcare And Pharmaceuticals
Gynofem Healthcare And Pharmaceuticals Limited (GHAPL) is a Public Limited Indian Non-Government Company incorporated in India on 13 October 2022 (Two years and three months 26 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.92 Cr.
The company currently has active open charges totaling ₹6.50 M.
Nishi Joshi, Anurag Mendhe, and Kartikay Joshi serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290MP2022PLC063077
-
Company No.
063077
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
13 Oct 2022
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Gynofem Healthcare And Pharmaceuticals?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Nishi Joshi | Director | 13-Oct-2022 | Current |
Anurag Mendhe | Director | 13-Oct-2022 | Current |
Kartikay Joshi | Director | 13-Oct-2022 | Current |
Financial Performance of Gynofem Healthcare And Pharmaceuticals.
Gynofem Healthcare And Pharmaceuticals Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Gynofem Healthcare And Pharmaceuticals?
In 2023, Gynofem Healthcare And Pharmaceuticals had a promoter holding of 79.84% and a public holding of 20.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.65 Cr
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.65 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
02 Feb 2024 | Axis Bank Limited | ₹6.50 M | Open |
How Many Employees Work at Gynofem Healthcare And Pharmaceuticals?
Gynofem Healthcare And Pharmaceuticals has a workforce of 52 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gynofem Healthcare And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gynofem Healthcare And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.